Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Inadequate glycemic control on diet/exercise therapy and ipragliflozin monotherapy~* HbA1c ≥7.0% and ≤10.0% before study start~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation, sitagliptin within 8 weeks prior to study participation.~* Currently has a urinary tract infection or genital infection with subjective symptom

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + Ipragliflozin (Type: EXPERIMENTAL): Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
- Placebo + Ipragliflozin (Type: ACTIVE_COMPARATOR): Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).